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IC50 = 83.4 ± 1.1 nM







































































































































































































































































































































































































































TCMDC-124168 Not	active 991 0.4	±	3.1
TCMDC-125274 9.7	±	0.5 1090 4.3	±	3.5
TCMDC-125529 12.9	±	2.4 830 20.4	±	5.4
TCMDC-125600 16.0	±	0.9 168 23.1	±	1.0
TCMDC-125577 27.7	±	4.4 524 27.7	±	4.2
TCMDC-123486 13.7	±	3.4 512 28.2	±	7.1
TCMDC-125788 18.4	±	3.0 761 32.8	±	4.58
TCMDC-125671 7.8	±	1.9 614 33.1	±	2.6
TCMDC-124822 16.8	±	1.8 874 37.7	±	4.0
TCMDC-123692 17.5	±	1.5 814 39.6	±	7.0
TCMDC-124421 16.6	±	0.6 718 39.8	±	23.7
TCMDC-125530 8.4	±	1.0 659 39.8	±	3.1
TCMDC-124969 25.1	±	3.0 647 45.8	±	8.4
TCMDC-124423 14.3	±	1.3 378 48.4	±	13.2





















MMV011895 12.2	±	2.0 135	±	4 156	±	6 1.2 0.2	±	3
MMV007384 10.6	±	2.6 2165	±	151a 3469	±	24b 1.6 18	±	6
MMV666607 22.7	± 1.5 260	±	23 458	±	28 1.8 26	±	2
MMV006767 14.8	±	1.7 782	±	35 1564	±	77 2.0 35	±	7
MMV665888 13.1	±	2.5 1410	±	47 1305	±	98 0.9 28	±	2
MMV665799 16.0	±	2.3 1639	±	23 2765	±	34 1.7 49	±	2
MMV020750 9.1	±	2.1 366	±	15 466	±	22 1.3 0.3	±	3
MMV007273 8.7	±	2.1 262	±	62 351	±	2 1.3 21	±	2
MMV000753 14.0	±	4.9 1212	±	4 1609	±	77 1.3 21		±	4



























































E01 NAc 492.0	±	73.6 1046	±	23 2.13
E02 80.7	±	1.7 108.5	±	10.8 132.1	±	0.0 1.22
E03 NA 276.0	±	29.7 413.4	±	2.8 1.50
E04 NA 147.0	±	10.0 232.9	±	1.5 1.58
E05 NA 6316	±	332 7257	±	167 1.15
E06 NA 3728	±	431 3693	±	167 0.99
E07 NA 97.7	±	10.7 144.3	±	11.0 1.48
E08 NA 95.1	±	23.7 168.8	±	14.0 1.77
E09 NA 190.3	±	4.2 277.7	±	53.7 1.46
E10 109.3	±	7.1 84.1	±	2.7 124.3	±	19.9 1.48
E11 101.2	±	7.7 123.4	±	3.2 166.3	±	21.1 1.35
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Unbound SYBR Green I 
Bound SYBR Green I 










U PYR = 9.5 nM
ART = 10.8 nM
CQ = 15.2 nM
ATV = 1.3 nM
Lysis  
Antimalarials 72 hours 37 °C 
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FU PYR = 9.5 nM
ART = 10.8 nM
CQ = 15.2 nM
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-123466 99 16.7 1.5 0.277
TCMDC-123486 95 13.7 3.4 0.512
TCMDC-123506 96 375.8 NC 0.134
TCMDC-123601 91 27.5 8.8 0.890
TCMDC-123680 100 16.7 0.01 0.267
TCMDC-123692 100 17.5 1.5 0.814
TCMDC-124127 94 15.3 1.3 1.117
TCMDC-124421 100 16.6 0.6 0.718
		 120	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-124423 100 14.3 1.3 0.378
TCMDC-124526 99 15.2 1.2 1.588
TCMDC-124822 91 16.8 1.8 0.874
TCMDC-124969 99 25.1 3.0 0.647
TCMDC-124972 97 14.5 2.8 1.054
TCMDC-125220 94 12.1 2.5 0.799
TCMDC-125274 100 9.7 0.5 1.090
TCMDC-125364 100 46.6 4.2 0.646
		 121	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-125415 95 19.3 1.2 0.258
TCMDC-125505 99 8.9 0.3 0.774
TCMDC-125529 99 12.9 2.4 0.830
TCMDC-125530 100 8.4 1.0 0.659
TCMDC-125577 98 27.7 4.4 0.524
TCMDC-125600 95 16.0 0.9 0.168
TCMDC-125671 100 7.8 1.9 0.614
TCMDC-125788 100 18.4 3.0 0.761
		 122	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-131238 100 62.1 4.4 0.927
TCMDC-132028 95 38.5 1.6 0.167
TCMDC-132120 92 29.1 8.3 1.244
TCMDC-132130 101 15.7 0.1 0.161
TCMDC-132131 97 9.9 0.9 0.889
TCMDC-132135 100 13.7 0.4 0.633
TCMDC-132141 99 12.4 0.3 0.789
TCMDC-132143 94 15.3 2.0 1.743
		 123	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132144 92 17.6 1.2 0.767
TCMDC-132145 98 14.7 1.3 0.452
TCMDC-132159 100 14.4 0.4 0.302
TCMDC-132160 96 20.6 2.6 0.557
TCMDC-132167 100 13.8 0.7 0.313
TCMDC-132178 102 16.5 0.03 0.793
TCMDC-132189 98 16.2 1.0 0.829
TCMDC-132192 99 15.4 0.5 0.323
		 124	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132201 100 11.2 1.3 0.410
TCMDC-132320 98 21.6 0.6 0.519
TCMDC-132405 98 11.1 2.8 0.119
TCMDC-132419 100 26.2 3.9 0.090
TCMDC-132558 100 14.2 0.8 0.194
TCMDC-132566 98 15.6 0.6 0.255
TCMDC-132571 100 16.1 1.4 0.396
TCMDC-132695 90 48.0 7.1 0.907
		 125	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132710 100 16.9 0.1 0.148
TCMDC-132729 99 16.4 2.2 0.130
TCMDC-132821 91 34.0 2.1 0.607
TCMDC-132829 97 36.7 13.0 0.772
TCMDC-132840 90 26.6 13.0 0.670
TCMDC-132845 94 12.2 0.2 0.099
TCMDC-132846 100 15.4 0.7 0.119
TCMDC-132849 95 23.1 5.8 0.117
		 126	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132854 92 18.6 1.6 0.115
TCMDC-132857 92 50.5 3.7 0.170
TCMDC-132862 100 25.5 11.8 0.910
TCMDC-132897 96 14.8 1.1 0.138
TCMDC-132898 98 18.4 3.4 0.184
TCMDC-132906 94 16.5 1.2 0.156
TCMDC-132910 99 23.2 3.5 0.200
TCMDC-132915 97 16.2 0.4 0.062
		 127	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132947 92 20.0 0.8 0.156
TCMDC-132958 93 15.1 1.5 0.157
TCMDC-133009 98 41.6 2.2 0.308
TCMDC-133042 95 16.3 1.4 0.146
TCMDC-133044 94 17.1 0.9 0.140
TCMDC-133052 91 14.6 0.04 0.215
TCMDC-133135 93 14.8 0.1 0.277
TCMDC-133136 92 17.6 0.5 0.170
		 128	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133155 91 12.8 0.5 0.715
TCMDC-133158 90 16.2 2.1 0.231
TCMDC-133171 99 25.5 3.9 0.756
TCMDC-133177 90 14.5 1.8 0.199
TCMDC-133194 98 21.6 2.1 0.104
TCMDC-133210 92 29.7 0.4 0.351
TCMDC-133257 99 22.9 2.0 0.630
TCMDC-133460 94 65.6 0.8 0.978
		 129	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133550 94 18.9 2.2 0.837
TCMDC-133699 97 14.7 1.1 0.738
TCMDC-133701 98 18.4 2.6 0.240
TCMDC-133702 99 25.4 4.5 0.534
TCMDC-133705 94 28.8 7.1 0.572
TCMDC-133932 98 26.8 3.4 0.142
TCMDC-133935 96 39.1 1.5 0.147
TCMDC-133940 96 36.3 4.1 0.142
		 130	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133941 100 17.3 0.6 0.153
TCMDC-134151 95 15.6 1.7 0.149
TCMDC-134493 100 41.6 3.7 0.860
TCMDC-135054 99 14.0 0.8 0.930
TCMDC-135247 92 NC NC 0.698
TCMDC-135248 91 15.6 2.5 0.570
TCMDC-135250 99 15.8 0.7 0.975
TCMDC-135305 97 306.5 NC 0.213
		 131	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-135360 92 35.6 5.1 0.906
TCMDC-135405 100 14.3 1.1 0.138
TCMDC-135406 93 11.9 3.6 0.111
TCMDC-135456 97 49.3 2.7 0.832
TCMDC-135478 94 16.2 0.01 0.197
TCMDC-135507 99 14.9 1.9 0.174
TCMDC-135542 91 16.0 5.5 0.109
TCMDC-135557 95 14.3 0.9 0.279
		 132	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-135688 100 24.0 0.1 0.832
TCMDC-135912 92 20.2 3.8 0.754
TCMDC-135945 100 27.6 5.3 0.840
TCMDC-136145 99 18.6 1.5 0.804
TCMDC-136152 100 19.1 5.9 0.828
TCMDC-136194 99 13.7 0.2 1.510
TCMDC-136243 100 16.1 0.3 0.888
TCMDC-136287 100 7.0 1.4 0.122
		 133	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136818 95 18.9 5.3 0.990
TCMDC-136819 90 23.8 8.8 0.238
TCMDC-136820 96 15.4 4.2 0.204
TCMDC-136824 92 12.6 1.2 0.134
TCMDC-136830 99 9.7 2.4 0.065
TCMDC-136831 101 9.0 1.5 0.265
TCMDC-136837 98 14.6 1.3 0.726
TCMDC-136853 100 33.7 11.1 1.087
		 134	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136859 99 14.8 0.5 0.585
TCMDC-136862 100 16.7 0.7 0.733
TCMDC-136906 97 14.9 1.2 1.088
TCMDC-136913 94 15.1 1.0 0.643
TCMDC-136914 92 14.3 5.5 0.454
TCMDC-136922 96 19.3 1.9 0.363
TCMDC-136923 99 21.1 6.4 0.612
TCMDC-136927 91 15.6 2.1 0.228
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136940 95 51.6 10.3 1.025
TCMDC-136941 91 36.0 20.6 0.797
TCMDC-136946 92 35.0 8.3 0.806
TCMDC-136951 97 14.2 1.2 0.688
TCMDC-136954 92 25.8 10.2 0.789
TCMDC-136957 90 15.4 2.7 0.719
TCMDC-136960 90 19.7 3.6 0.681
TCMDC-136961 92 15.0 0.9 0.278
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136965 100 35.3 14.2 0.236
TCMDC-136966 101 11.6 1.8 0.497
TCMDC-136970 93 18.0 3.2 1.045
TCMDC-136992 97 21.2 0.1 0.635
TCMDC-136993 101 14.1 1.1 0.627
TCMDC-136998 99 11.2 2.5 0.596
TCMDC-137034 98 10.6 0.03 0.857
TCMDC-137037 91 17.0 2.7 0.581
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137059 100 24.1 4.4 0.735
TCMDC-137063 100 15.7 2.4 0.167
TCMDC-137065 92 34.1 5.8 0.560
TCMDC-137067 91 19.1 4.1 0.670
TCMDC-137068 93 25.8 0.2 0.645
TCMDC-137072 100 7.1 1.0 0.651
TCMDC-137087 101 12.8 2.4 0.630
TCMDC-137092 100 21.8 1.4 0.958
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137094 98 10.1 2.6 0.289
TCMDC-137110 90 48.4 0.5 0.413
TCMDC-137120 99 11.5 3.0 0.552
TCMDC-137125 97 15.8 0.3 0.182
TCMDC-137129 98 9.8 2.5 0.185
TCMDC-137131 95 9.2 1.0 0.232
TCMDC-137135 97 32.3 9.4 0.715
TCMDC-137136 92 23.5 3.2 0.388
		 139	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137137 99 15.5 0.9 0.505
TCMDC-137180 99 16.8 2.8 1.477
TCMDC-137212 100 17.0 3.4 0.035
TCMDC-137480 98 117.9 NC 0.104
TCMDC-137481 100 14.9 0.5 0.152
TCMDC-137582 98 15.6 0.3 0.104
TCMDC-137793 91 84.7 16.6 0.143
TCMDC-137869 100 14.5 0.7 0.168
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137902 96 55.6 12.4 0.376
TCMDC-137983 100 43.1 0.6 0.395
TCMDC-138197 100 20.8 7.3 0.174
TCMDC-138205 98 9.8 2.4 0.111
TCMDC-138256 94 20.1 5.0 0.445
TCMDC-138432 100 50.0 50.6 0.237
TCMDC-138451 99 34.5 22.0 0.186
TCMDC-138467 93 13.2 1.9 0.557
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-138486 100 16.2 1.4 0.132
TCMDC-138520 100 15.5 1.8 0.335
TCMDC-138557 99 47.4 3.0 0.776
TCMDC-138659 93 15.0 4.1 0.915
TCMDC-138660 94 10.3 0.2 0.608
TCMDC-138686 98 47.1 0.5 0.818
TCMDC-138696 99 12.2 0.4 0.716
TCMDC-138752 100 11.7 4.5 0.278
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-138898 100 44.6 1.3 0.925
TCMDC-138911 100 25.6 0.9 0.751
TCMDC-139008 99 57.1 4.4 1.161
TCMDC-139205 100 NC NC 0.530
TCMDC-139268 98 37.3 4.8 0.158
TCMDC-139383 93 20.5 2.9 0.573
TCMDC-139406 92 23.8 10.4 0.695
TCMDC-139410 97 12.5 2.9 0.256
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-139498 100 17.5 0.6 0.314
TCMDC-139502 99 25.3 3.8 0.063
TCMDC-139550 100 22.4 1.0 0.114
TCMDC-139559 98 9.0 2.7 1.006
TCMDC-139871 96 42.0 4.4 0.776
TCMDC-140218 93 15.2 0.7 0.911
TCMDC-140319 100 22.4 8.0 1.168
TCMDC-140344 100 34.4 2.3 0.514
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-140347 100 21.4 1.6 0.894
TCMDC-140367 95 20.1 0.9 0.734
TCMDC-140540 91 14.3 1.2 0.684
TCMDC-140648 90 16.4 2.7 1.120
TCMDC-140681 98 14.6 0.7 0.464
TCMDC-140797 98 15.7 2.5 0.895
TCMDC-140827 92 30.5 4.6 0.759
TCMDC-141000 99 12.6 1.9 0.135
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-141338 100 15.0 1.6 0.978
TCMDC-141388 100 13.5 0.1 0.121
TCMDC-141392 95 15.7 3.2 0.617
TCMDC-141399 97 20.4 2.6 0.762
TCMDC-141560 100 12.3 2.1 0.801
TCMDC-141561 93 15.2 0.2 1.018
TCMDC-141584 93 19.8 1.3 0.344
TCMDC-141585 100 44.0 2.6 0.531
		 146	
Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-141609 100 13.9 0.3 0.272
TCMDC-141610 97 14.7 1.4 0.287
TCMDC-141611 99 13.1 1.6 0.859
TCMDC-141612 100 16.3 0.8 0.736
TCMDC-141978 96 11.2 2.4 0.983
TCMDC-142040 100 13.3 0.1 0.202
TCMDC-142048 94 9.1 0.5 0.030
TCMDC-142308 100 12.8 0.7 0.873
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-142335 94 49.9 0.3 0.253
